Last updated: March 13, 2026
What Is NDC 82009-0108?
NDC 82009-0108 refers to a specific drug product listed in the United States National Drug Code (NDC) portal. Based on available data, it is identified as Erenumab-aooe (Aimovig), a monoclonal antibody used for migraine prevention. The drug is developed by Amgen and Novartis.
Market Overview
Market Size and Growth
The global migraine therapeutics market was valued at around USD 4 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of approximately 2.8% through 2028 [1]. This growth is driven by increasing prevalence, improved diagnosis, and advancements in biologic therapeutics.
In the U.S., migraine affects over 39 million people, with an estimated 10-15% of the population experiencing at least one migraine per year [2]. The annual treatment market for migraine, including both acute and preventative therapies, exceeds USD 1.5 billion.
Competition and Market Dynamics
Key competitors in the preventive migraine treatment class include:
- Erenumab (Aimovig) by Amgen/Novartis
- Eptinezumab (Vyepti) by Lundbeck
- Dulaglutide (Trulicity) off-label in some cases
- Topiramate and other small molecule preventives
Erenumab holds a significant market share due to its first-mover advantage and FDA approval in 2018.
Regulatory and Reimbursement Landscape
The drug has FDA approval for preventive treatment of episodic and chronic migraines in adults. Reimbursement policies favor biologics like erenumab due to perceived efficacy and safety profiles, though high costs limit broader access.
Price Analysis
Current Pricing
The wholesale acquisition cost (WAC) for Erenumab-aooe (Aimovig) is approximately USD 6,900 per year of therapy, based on a monthly injection costing around USD 575 [3]. Insurance coverage often reduces out-of-pocket expenses, but high list prices impact overall market penetration.
Pricing Trends
Since market entry, prices for biologic migraine preventives have remained stable, with minor adjustments due to competition and inflation. The introduction of biosimilars or generics is not expected in the near term due to patent protections and manufacturing complexities.
Future Price Projections
Price reductions for biologics like erenumab are unlikely in the next 3-5 years, considering:
- Brand dominance
- Complexity of biosimilar development
- Reimbursement incentives
However, price competition could emerge if bios Uber biosimilar development accelerates, particularly in Europe, where regulatory pathways are more permitting.
Estimated future prices:
| Time Frame |
Projected Annual Cost |
Factors Influencing Price |
| 2023-2024 |
USD 6,900 |
Stable, no biosimilar entry |
| 2025-2026 |
USD 6,500 – 6,900 |
Possible minor discounts, improved payer negotiations |
| 2027-2028 |
USD 6,200 – 6,500 |
Emergence of biosimilars, increased competition |
Market Entry and Expansion Factors
- Increased prevalence of migraines boosts demand.
- Improved payer access and insurance coverage expand market reach.
- Potential biosimilar development could pressure pricing.
Key Takeaways
- NDC 82009-0108 corresponds to Erenumab-aooe (Aimovig), a leading preventive migraine biologic.
- The global migraine market grows around 2.8% annually; the U.S. market exceeds USD 1.5 billion.
- Current pricing is approximately USD 6,900 annually; prices are stable but could see slight declines due to future biosimilar competition.
- Market expansion hinges on increased diagnosis, insurance coverage, and competition mitigation.
- Biosimilar entry remains unlikely before 2025, maintaining current pricing structure.
FAQs
1. What is the primary indication for NDC 82009-0108?
Prevention of episodic and chronic migraines in adults.
2. How does the price of erenumab compare to oral migraine preventives?
Erenumab costs approximately USD 6,900 annually. Oral preventives like topiramate are typically under USD 200 per year, making biologics significantly more expensive.
3. Are biosimilars expected for erenumab?
Potentially, but regulatory and patent protections delaying biosimilar market entry until at least 2025, if not later.
4. What factors may influence future prices?
Patent protections, competition from biosimilars, payer negotiations, and manufacturing costs.
5. How does the drug’s efficacy influence market size?
High efficacy and safety profile favor increased adoption, expanding the market size.
References
[1] MarketsandMarkets. (2022). Migraine therapeutics market by disease type, drug class, and region - forecast to 2028.
[2] American Migraine Foundation. (2021). Migraine statistics.
[3] GoodRx. (2023). Erenumab (Aimovig) cost.
[4] FDA. (2018). Erenumab (Aimovig) approval notice.
